Ave Maria Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ave Maria Biotech is a private, pre-revenue diagnostics company developing the BD-500, a real-time airborne virus detector. Conceived in response to the COVID-19 pandemic, the device aims to provide immediate, actionable data on airborne pathogens to enable targeted interventions in settings like military bases, hospitals, and cruise ships. The company's strategy involves leveraging government partnerships, such as a CRADA with the U.S. military, and targeting large institutional markets to address the global demand for pandemic preparedness infrastructure.

Infectious Disease

Technology Platform

Networked real-time airborne pathogen detection system (BD-500) providing environmental monitoring and centralized data analytics.

Opportunities

The massive global spend on pandemic response has created a dedicated budget for preparedness technologies in governments and large institutions.

Securing an initial flagship partnership, such as with the U.S.

military or a major cruise line, would provide critical validation and a reference customer to accelerate adoption across other targeted verticals like senior living and hospitals.

Risk Factors

The core technology lacks publicly disclosed third-party validation and regulatory status, creating performance and adoption risk.

The business model relies on capital expenditures for preparedness, which may face budget pressure outside of active health crises.

The company faces competition from other emerging biodetection firms and must execute complex sales cycles with large, bureaucratic organizations.

Competitive Landscape

The competitive landscape includes companies developing environmental monitoring and air quality sensors, as well as firms specializing in rapid pathogen detection for biodefense and healthcare settings. Competitors range from large defense contractors with CBRN divisions to smaller startups leveraging CRISPR, biosensors, or aerosol mass spectrometry. Ave Maria's differentiator is its emphasis on a networked system for real-time, location-specific actionable data across large facilities.

More companies in Diagnostics & Precision Medicine →More companies in United States →